|
01 Jun 2025 |
Divi's Laboratories
|
Consensus Share Price Target
|
6612.00 |
6364.73 |
- |
-3.74 |
hold
|
|
|
|
|
22 May 2023
|
Divi's Laboratories
|
ICICI Securities Limited
|
6612.00
|
3560.00
|
3265.00
(102.51%)
|
Target met |
Accumulate
|
|
|
Divi’s Laboratories’ (Divi’s) has posted its highest ever quarterly sales in generics segment of Rs10bn, up 42% YoY in Q4FY23, though a surge in raw material price and overhead cost has impacted margins (down 1,670bps YoY). Management has indicated a gradual improvement in margins Q1FY24 onwards as it has exhausted high-priced inventory and raw material prices are also declining.
|
|
21 May 2023
|
Divi's Laboratories
|
ICICI Direct
|
6612.00
|
3575.00
|
3098.30
(113.41%)
|
Target met |
Buy
|
|
|
|
|
21 May 2023
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
6612.00
|
2700.00
|
3098.30
(113.41%)
|
|
Hold
|
|
|
|
|
19 Mar 2023
|
Divi's Laboratories
|
Motilal Oswal
|
6612.00
|
2620.00
|
2791.50
(136.86%)
|
|
Neutral
|
|
|
|
|
06 Feb 2023
|
Divi's Laboratories
|
ICICI Securities Limited
|
6612.00
|
3024.00
|
2884.35
(129.24%)
|
Target met |
Hold
|
|
|
Divi’s Laboratories’ (Divi’s) Q3FY23 performance was well below our estimates. Consolidated revenues fell 7.9% QoQ to Rs17.1bn (I-Sec: Rs20.5bn), EBITDA margin slipped to its lowest-ever at 23.9% (-2,010bps YoY, -960bpsQoQ)
|
|
05 Feb 2023
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
6612.00
|
2700.00
|
2884.35
(129.24%)
|
|
Hold
|
|
|
|
|
04 Feb 2023
|
Divi's Laboratories
|
BOB Capital Markets Ltd.
|
6612.00
|
3200.00
|
2884.35
(129.24%)
|
Target met |
Hold
|
|
|
Q3 disappoints as revenue/PAT of Rs 17bn/Rs 3bn missed consensus by 12%/38%
|
|
04 Feb 2023
|
Divi's Laboratories
|
Motilal Oswal
|
6612.00
|
2620.00
|
2884.35
(129.24%)
|
|
Neutral
|
|
|
|
|
03 Feb 2023
|
Divi's Laboratories
|
ICICI Direct
|
6612.00
|
2945.00
|
2884.35
(129.24%)
|
Target met |
Hold
|
|
|
|
|
11 Nov 2022
|
Divi's Laboratories
|
SMC online
|
6612.00
|
|
3271.40
(102.12%)
|
|
Results Update
|
|
|
|